This is a phase II study for patients with squamous cell carcinoma of the head and neck who
have residual disease following definitive therapy with radiation (with or without systemic
therapy). Patients must be diagnosed with residual disease within 24 weeks of completion of
radiation therapy. Residual disease must be biopsy proven before the patient can consent to
the trial, and can be either from lymph nodes in the neck, or from the primary tumor site.
Prior to beginning study therapy patients are evaluated by an ENT to determine if they have
disease amenable to surgical resection. Both resectable and unresectable patients will be
eligible for participation in the study.